|
Diurnal Group PLC on Friday said its Efmody treatment has been recommended as an option to treat patients with congenital adrenal hyperplasia.
Diurnal is a Cardiff-based pharmaceutical company focused on hormonal diseases. Its treatment was recommended by the All Wales Medicines Strategy Group as an option for restricted use in NHS Wales.
The recommendation means Efmody is available as a second-line treatment option in adolescents with congenital adrenal hyperplasia and as third-line treatment in adults with the disease.
In both cases, the treatment is restricted to patients who are not adequately controlled on maximum guideline doses of immediate-release hydrocortisone.
Efmody is a preparation of hydrocortisone that has been specifically designed to mimic the circadian rhythm of cortisol. It is designed to control androgen excess and chronic fatigue in patients with diseases of cortisol deficiency.
Congenital adrenal hyperplasia refers to a group of genetic disorders that affect the adrenal glands, a pair of small organs above the kidneys. The adrenal glands produce important hormones, including Cortisol, which regulates the body's response to illness or stress.
Diurnal will commercially roll-out Efmody in Wales using its existing sales and marketing infrastructure and supply chain.
Interim Chief Executive Officer Richard Bungay commented: ‘We are delighted that, after a rigorous review, the All Wales Medical Strategy Group has recognised the potential for Efmody to address important unmet needs in patients suffering with congenital adrenal hyperplasia. Diurnal believes the use of this medicine will improve the lives of adults and adolescents in Wales living with this rare disease.’
Shares in Diurnal were trading 0.9% lower at 26.90 pence each in London on Friday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
